For over 12 years, dQ&A has gathered primary data from diabetes healthcare practitioners (HCPs)—notably endocrinologists and primary care physicians—expanding our ‘Prescriber Perspectives’ tracker to five countries with insights from key prescribers and influencers.
dQ&A reveals how Walmart’s CareZone deal, low mail-order NPS scores, and a pandemic push toward home delivery are reshaping pharmacy apps for diabetes.
Our hearts are heavy at the pain felt by the Black community. We are committed to working towards a more equitable future, and we invite you to join us.
Our third COVID-19 survey of U.S. diabetes patients found high infection concern, income loss, care changes, and challenges accessing healthy food and supplies.
dQ&A analyzes telemedicine diabetes care during COVID-19—trends, patient experiences, and what's next for virtual visits amid evolving healthcare needs.
Our survey of Canada’s type 1 diabetes community reveals COVID-19’s impact on medication access, diet, exercise, hyperglycemia, and overall well-being.
Our April 2020 dQ&A survey of 4,700 U.S. diabetes patients finds supply chains largely intact yet short-term delays and risky pharmacy visits hinder refills.
Our second COVID-19 impact survey of 4,500+ U.S. diabetes patients found ongoing drug/supply delays, care disruptions, and declines in diet and exercise.
Our study of US patients explores insulin rationing’s physical & emotional impact through qualitative & quantitative research. Check out the community video.
